3 completed, 1 active not recruiting, 1 no longer available, 1 recruiting. 2 Phase 1, 1 Not applicable.
By phase and status
Follow Acinetobacter Baumannii Infection: new trials by email Literature Review of Acinetobacter Baumannii Infection trials Research Report on Acinetobacter Baumannii Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
Cefoperazone-sulbactam injection, Ampicillin - Sulbactam Injection - Acinetobacter Baumannii Infection | Not applicable | Recruiting | Cairo University | 50 | 2025-05-01 | 2025-08-12 |
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection | | Active not recruiting | National Institutes of Health Clinical Center (CC) | 5000 | 2025-01-01 | 2025-11-10 |
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
ETX2514SUL - Acinetobacter Baumannii Infection | Phase 1 | Completed | Entasis Therapeutics | 34 | 2017-10-03 | 2018-06-14 |
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
ETX2514, Placebo, Sulbactam - Acinetobacter Baumannii Infection | Phase 1 | Completed | Entasis Therapeutics | 124 | 2016-10-01 | 2017-06-05 |
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection
None intervention - Acinetobacter Baumannii Infection | | Completed | Southeast University, China | 40 | 2015-07-01 | 2016-09-01 |
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Therapy - Covid19, Bacteremia | | No longer available | Adaptive Phage Therapeutics, Inc. | | | 2021-12-21 |
Narrower conditions
Infections (3) · Bacteremia (1) · COVID-19 (1) · Pseudomonas Infections (1) · Renal Insufficiency (1) · Sepsis (1) · Staphylococcal Infections (1)
Broader conditions
Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gram-Negative Bacterial Infections (1) · Gram-Positive Bacterial Infections (1) · Inflammation (1) · Kidney Diseases (1) · Lung Diseases (1) · Male Urogenital Diseases (1) · Nidovirales Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Interventions
Cilastatin, Imipenem Drug Combination (1) · Phage Therapy (1) · Sulbactam (1) · durlobactam (1) · sultamicillin (1)
Sponsors
Entasis Therapeutics (2) · Adaptive Phage Therapeutics, Inc. (1) · Cairo University (1) · National Institutes of Health Clinical Center (CC) (1) · Southeast University, China (1)
Countries
United States (2) · Australia (1) · Egypt (1)
Top investigators
Ahmed M Mukhtar, Professor Anesthesia and ICU (1) · Jason Lickliter (1) · Sameer Kadri, MD (1)
Results publications
PMID 32284380